BTG Deals Its Way Into Interventional Medicine

UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.

IV1608_BTG Feature Image_1200x675px

UK-listed company BTG PLC has a simple business strategy for success in a highly competitive sector: Target patient populations that are poorly served by existing treatment options, and that are cared for by specialist physicians with whom BTG can partner in a drive to deliver better health care.

The company also employs a refreshing transparency about its activities and conveys a good deal of confidence in its portfolio...

More from Business Strategy

More from In Vivo